Voyager Therapeutics, Inc.: insider trades · United States · SEC (Form 4)

About Voyager Therapeutics, Inc.

Voyager Therapeutics, Inc. is a U.S.-listed biotechnology company traded on the Nasdaq Global Select Market under the ticker VYGR, and based in the United States. Its corporate headquarters are in Lexington, Massachusetts, in the greater Boston life sciences cluster. The company was launched in 2014 with support from Third Rock Ventures and was originally built around gene therapy programs for central nervous system disorders. Over time, Voyager has expanded into a broader neuroscience-focused platform aimed at leveraging human genetics to alter the course of neurological disease. ([voyagertherapeutics.com](https://www.voyagertherapeutics.com/?utm_source=openai)) Voyager’s strategic identity is highly focused: it seeks to use genetic medicine to address severe, often chronic neurological diseases with major unmet medical need. That focus differentiates it from larger diversified pharma groups and also from many gene therapy peers, because Voyager concentrates its scientific, clinical, and capital resources on neurology and on delivery technologies designed to reach the brain across the blood-brain barrier. The company combines wholly owned programs with select collaborations, helping it share development risk while retaining meaningful upside in key assets. ([voyagertherapeutics.com](https://www.voyagertherapeutics.com/?utm_source=openai)) On the business-line side, Voyager’s pipeline includes gene therapy and gene-silencing assets in Alzheimer’s disease, including tau-targeting programs, as well as programs in Parkinson’s disease, Friedreich’s ataxia, and GBA1-related diseases. In 2025, the company added a fourth wholly owned Alzheimer’s program centered on APOE, strengthening its Alzheimer’s franchise. Voyager is also developing Voyager NeuroShuttle™, a non-viral delivery platform designed for brain delivery, which highlights the company’s effort to broaden its modality mix beyond traditional viral vectors. ([voyagertherapeutics.com](https://www.voyagertherapeutics.com/pipeline-overview/?utm_source=openai)) From a competitive standpoint, Voyager remains a research- and development-driven biotech, meaning equity value is primarily tied to clinical data, regulatory milestones, partnering activity, and the ability to translate platform science into human proof of concept. Its core advantage is deep specialization in neurological disease, a segment that is scientifically challenging but potentially very large. Geographically, Voyager’s footprint is concentrated in the United States, with headquarters and operating activities centered in the Boston/Lexington, Massachusetts area. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1640266/000155837025002703/vygr-20241231x10k.htm?utm_source=openai)) Recent catalysts have been important. In 2025 and early 2026, Voyager highlighted progress across its tau assets in Alzheimer’s disease, planned clinical entry for several I.V.-delivered neuro gene therapies, and advancement of its NeuroShuttle platform. Management also stated that its cash runway extends into 2028, an important consideration for biotech investors assessing dilution risk and funding durability. For francophone investors, VYGR is therefore a U.S.-market Nasdaq biotechnology name with a pure-play neuroscience angle, where the investment case is driven by pipeline execution rather than current product sales. ([ir.voyagertherapeutics.com](https://ir.voyagertherapeutics.com/news-releases/news-release-details/voyager-reports-fourth-quarter-and-full-year-2025-financial-and?utm_source=openai))